| Course | NU 623 Adult Healthcare |
|---|---|
| Unit | Unit 2 |
| Paper type | Cardiovascular risk stratification write-up |
| Length | About 1,030 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN Family Nurse Practitioner |
| Updated | October 2026 |
Free sample paper for NU 623 Unit 2
Ten-Year Cardiovascular Risk in a 55-Year-Old South Asian Man: What the Pooled Cohort Equations Say and Do Not Say
Student Name
Department of Nursing, Herzing University
NU 623: Adult Healthcare
Instructor Name
January 29, 2026
Ten-Year Cardiovascular Risk in a 55-Year-Old South Asian Man: What the Pooled Cohort Equations Say and Do Not Say
The Patient and the Clinical Question
Mr. S., a composite 55-year-old software engineer born in India who has lived in the United States for 25 years, comes for a wellness visit. He has no known cardiovascular disease, diabetes, or kidney disease, and he does not smoke. Heart disease runs early in his family: his father died of a heart attack at 52, and his older brother needed a coronary stent at 49. He walks 30 minutes most days. The clinical question the risk estimate must inform is whether he should start a statin for primary prevention of atherosclerotic cardiovascular disease (ASCVD), and if the answer is unclear, what further information would settle it.
The Instrument
The Pooled Cohort Equations estimate the 10-year risk of a first ASCVD event, defined as nonfatal myocardial infarction, coronary death, or fatal or nonfatal stroke, in adults 40 to 79 without known ASCVD (Goff et al., 2014). They were derived from several large community cohorts in the United States that included White and African American participants. For people of other races and ethnicities, the calculator uses the equations for White individuals. Validation studies have shown that the equations often overestimate risk in contemporary populations, though calibration varies by group (DeFilippis et al., 2015). The newer PREVENT equations, developed by the American Heart Association from more recent and diverse cohorts, remove race as an input and add kidney function (Khan et al., 2024); both are discussed below.
Inputs
Age 55, from his date of birth. Sex male. Race entered as other, which the calculator treats using the White equations. Total cholesterol 214 mg/dL and high-density lipoprotein cholesterol 41 mg/dL, from a fasting lipid panel drawn one week ago. Systolic blood pressure 134 mm Hg, the average of two seated readings taken today after five minutes of rest, and he is not on blood pressure treatment. Diabetes no, confirmed by an A1C of 5.8% drawn with the lipid panel. Current smoker no; he has never smoked. Every input is from the past week, so the estimate reflects his current state rather than an older record. The same panel reported an LDL of 138 and triglycerides of 176 mg/dL; these are not calculator inputs, but they matter for interpretation.
Result
The Pooled Cohort Equations return a 10-year ASCVD risk of 7.2%. Under the 2019 prevention guideline categories, this falls in the borderline band, which runs from 5% to less than 7.5%, just below the intermediate band, which begins at 7.5%. For comparison, the calculator's estimate for a man of the same age with optimal risk factors is well under 5%, so his estimated risk is above that of an otherwise optimal peer but not dramatically so.
Interpretation
Taken alone, a borderline result would support a conversation about lifestyle and, if risk-enhancing factors are present, a discussion of moderate-intensity statin therapy (Arnett et al., 2019). The number is not the decision. It is a starting estimate built from six inputs, and it cannot know anything about him that those six values do not carry. The guideline explicitly directs clinicians to consider factors the equations do not capture.
Two such factors apply to Mr. S. The first is his family history of premature ASCVD, which the guideline counts when a father, brother, or son was affected before 55: both his father and his brother qualify. The second is South Asian ancestry, which the guideline lists as a risk-enhancing factor because people of South Asian descent have higher rates of ASCVD at younger ages than the equations predict (Arnett et al., 2019). His A1C of 5.8% indicates prediabetes, and his triglycerides and low high-density lipoprotein point in the same direction, a metabolic pattern that is common in South Asian adults and is also not captured by the equations.
Limitations of the Estimate for This Patient
Mr. S. does not resemble the derivation population. The cohorts included very few South Asian participants, and the calculator's use of the White equations for him is a default, not a validated choice. The overestimation found in modern cohorts may not apply to him; the direction of error for South Asian men may be the reverse, toward underestimation. The equations also ignore family history, prediabetes, and triglycerides. The PREVENT equations would not solve the ancestry problem, because they remove race entirely and were not designed to capture ancestry-specific risk, and they generally produce lower estimates than the Pooled Cohort Equations for the same person. A calculated 7.2% should therefore be treated as a floor rather than a precise value. The estimate also carries ordinary statistical uncertainty: a single lipid panel and one day's blood pressure readings can shift the result by a percentage point or more, which is enough to move him across the 7.5% boundary in either direction.
What Changes Because of the Estimate
Because his risk is borderline with two risk-enhancing factors, a statin is reasonable, and the decision is uncertain enough that a coronary artery calcium score would help. If his score is zero, it would be reasonable to defer a statin and repeat the assessment in five to ten years unless his risk factors change; if it is 1 to 99, a statin is favored; if it is 100 or higher, a statin is clearly indicated. Lifestyle measures apply regardless: dietary changes aimed at triglycerides and weight, more vigorous activity, and a repeat A1C in one year. A calculated risk that changed nothing would have informed nobody; this one moved the plan from routine follow-up to a specific test and a specific conversation.
What He Was Told and What He Chose
Mr. S. was told that the standard calculator puts his risk of a heart attack or stroke over ten years at about 7 in 100, that his family history and ancestry probably make his true risk higher, and that a calcium scan would show whether plaque has already started to form. He chose to have the calcium scan before deciding about a statin, and he agreed to start the dietary changes now. His choice is recorded along with the discussion.
References
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Munoz, D., Smith, S. C., Jr., Virani, S. S., Williams, K. A., Sr., Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596-e646. https://doi.org/10.1161/CIR.0000000000000678
DeFilippis, A. P., Young, R., Carrubba, C. J., McEvoy, J. W., Budoff, M. J., Blumenthal, R. S., Kronmal, R. A., McClelland, R. L., Nasir, K., & Blaha, M. J. (2015). An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Annals of Internal Medicine, 162(4), 266-275. https://doi.org/10.7326/M14-1281
Goff, D. C., Jr., Lloyd-Jones, D. M., Bennett, G., Coady, S., D'Agostino, R. B., Sr., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O'Donnell, C. J., Robinson, J. G., Schwartz, J. S., Shero, S. T., Smith, S. C., Jr., Sorlie, P., Stone, N. J., & Wilson, P. W. F. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation, 129(25 Suppl. 2), S49-S73. https://doi.org/10.1161/01.cir.0000437741.48606.98
Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., Blaha, M. J., Carson, A. P., Chang, A. R., Ciemins, E., Go, A. S., Gutierrez, O. M., Hwang, S.-J., Jassal, S. K., Kovesdy, C. P., Lloyd-Jones, D. M., Shlipak, M. G., Palaniappan, L. P., Sperling, L., ... Coresh, J. (2024). Development and validation of the American Heart Association's PREVENT equations. Circulation, 149(6), 430-449. https://doi.org/10.1161/CIRCULATIONAHA.123.067626
The Herzing NU 623 Unit 2 instructions
Unit 2 asks you to apply a validated risk assessment tool to an adult patient and interpret the result. Expect to name the tool and describe what it predicts, the population it was built on and its inputs. The write-up should list each input value, report the result and place it in the guideline's risk categories. Interpretation should consider factors the tool does not include, often called risk enhancers, and the limitations of the tool for this specific patient. Many sections ask how the result changes management and how it was communicated to the patient in plain terms. Cite the tool's derivation study, the relevant guideline and evidence on its performance in different populations, using APA 7. Page limits vary by section; build an invented patient, and pick a tool that is one your course has covered or approved.
Inside the NU 623 Unit 2 example
The sample opens with the patient and the question: does he need a statin? The instrument section explains that the Pooled Cohort Equations estimate a first atherosclerotic event over ten years in adults 40 to 79 and describes the cohorts they came from. The inputs section lists age, sex, race entry, cholesterol values, blood pressure, treatment status, diabetes and smoking, each with its source. The result is 7.2 percent, placed in the borderline band. Interpretation adds two risk-enhancing factors, ancestry and family history, which move the discussion toward therapy. The limitations section explains why the calculator may underestimate his risk. The management section supports a moderate-intensity statin or a coronary calcium score to refine the decision. The last section shows how the risk was explained as about 7 in 100 and records his choice.
NU 623 Unit 2 rubric: what full points look like
Herzing rubrics for risk stratification usually award points for selecting and describing the tool, accurate application, interpretation, limitations, management implications and writing. Tool points require the outcome, population and inputs to be described correctly with a citation to the derivation study. Application points depend on correct inputs and an accurate result placed in the right category. Interpretation is often weighted most heavily, and full credit goes to papers that add guideline risk enhancers rather than relying on the number alone. Limitations are credited when they are specific to this patient. Management points go to decisions that follow from the result and from shared decision making. Writing points cover clear structure, accurate units and APA citations for the guideline and studies on calibration in different groups.
NU 623 Unit 2 help: mistakes that cost points
The most common loss is reporting the score and stopping, without interpreting it or saying what changes. Students also enter inputs incorrectly, for example using an untreated blood pressure when the patient takes medication, or leave out how race was entered. Risk categories from older guidelines are another frequent error. Limitations are often generic, such as "no tool is perfect," instead of tied to the patient's ancestry or age. Many papers forget risk-enhancing factors, which the current guideline expects for borderline and intermediate results. The patient communication section is sometimes missing or full of jargon. Finally, a statin decision presented as automatic misses the shared decision the guideline describes for borderline risk.
Get a NU 623 Unit 2 example written to your instructions
Send the Unit 2 instructions and the rubric from your NU 623 classroom, plus the patient case and the tool your assignment specifies. We write a custom example that lists its inputs, interprets the result and says what changes because of it, returned in 24 to 48 hours. The first custom sample is free.
More NU 623 papers and FNP samples
- NU 623 Unit 1: Screening and prevention plan
- NU 623 Unit 3: Chronic disease management plan
- NU 623 Unit 4: Episodic visit documentation
- NU 623 Unit 5: Self-management support plan
- NU 623 Unit 6: Referral and consultation letter
- NU 623 Unit 7: Quality measure gap analysis
- NU 623 Unit 8: Panel management plan
- NU 636 Unit 2: Prescribing rationale
- NU 627 Unit 2: Functional and cognitive screening review
- NU 631 Unit 2: Contraception counseling record
- NU 632 Unit 2: Growth and development assessment
NU 623 Unit 2 questions, answered
Is it enough to report the score?
No, and that is where most of these lose marks. The calculation is the easy half; the paper is graded on interpretation. Say what the estimate means over its stated horizon, where it falls in the guideline bands, how it compares to a typical person of the same age, and what you would do differently because of it. A number with no decision attached has informed nothing.
Why does the derivation population matter?
Because a tool estimates risk for people like the ones it was built from. Several widely used instruments were derived in cohorts that under-represent parts of the population they are now applied to, and the resulting estimates can be systematically off. Naming the cohort and saying whether your patient resembles it is a straightforward way to demonstrate you understand what the tool is doing.
What if the score is low but I am still concerned?
Say so and explain why, because that is clinical reasoning rather than a contradiction. Risk instruments capture the variables in their model and nothing else, so a family history pattern, an occupational exposure or a finding on examination can sit entirely outside the calculation. Name what the tool missed and how it affected your judgment.
Where can I find a free NU 623 Unit 2 sample paper?
You can read the whole NU 623 Unit 2 write-up here at no cost, from the inputs and result to the limitations and the shared decision. For a different risk tool or patient, ask for a custom write-up; it is free and generally ready within a couple of days.
How do I interpret a borderline ASCVD risk score?
A ten-year risk of 5 to under 7.5 percent is borderline. Look for risk-enhancing factors such as family history, ancestry or chronic kidney disease; if present, a moderate-intensity statin is reasonable after discussion, and a coronary calcium score can help when the decision is uncertain.